{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:59:17Z","timestamp":1766401157381,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013093","name":"science and technology planning project of shenzhen municipality","doi-asserted-by":"publisher","award":["JCYJ20180302173532311"],"award-info":[{"award-number":["JCYJ20180302173532311"]}],"id":[{"id":"10.13039\/501100013093","id-type":"DOI","asserted-by":"publisher"}]},{"name":"shenzhen science and technology plan project","award":["JCYJ20170817094922513"],"award-info":[{"award-number":["JCYJ20170817094922513"]}]},{"name":"the sanming project of medicine in shenzhen","award":["SZSM201612080"],"award-info":[{"award-number":["SZSM201612080"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The objective was to evaluate whether initiation of urate-lowering treatment (ULT) during an acute gout flare prolonged the current episode.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A comprehensive search of MEDLINE and Web of Science databases was conducted from their inception to 15 March 2021. Five randomized controlled trials (RCTs) with 381 patients met the inclusion criteria. Standardized mean difference (SMD), odds ratio (OR), and 95% confidence interval (CI) were used for estimating the clinical efficacy of ULT in acute gout.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was no statistical difference in days to resolution (intent-to-treat analysis) (SMD, 0.68; 95% CI \u2212\u00a00.42 to 1.78; I<jats:sup>2<\/jats:sup>, 49%; <jats:italic>p<\/jats:italic>\u2009=\u20090.22), the pain visual analogue score (VAS) by day 10 (SMD, \u2212\u00a00.07; 95% CI \u2212\u00a00.30 to 0.16; I<jats:sup>2<\/jats:sup>, 0%; <jats:italic>p<\/jats:italic>\u2009=\u20090.53), C-reactive protein (CRP) from day 7 to 10 (SMD, \u2212\u00a01.14; 95% CI \u2212\u00a05.63 to 3.36; I<jats:sup>2<\/jats:sup>, 55%; <jats:italic>p<\/jats:italic>\u2009=\u20090.62), erythrocyte sedimentation rate (ESR) from day 7 to 10 (SMD, \u2212\u00a02.51; 95% CI \u2212\u00a05.46 to 0.45; I<jats:sup>2<\/jats:sup>, 0%; <jats:italic>p<\/jats:italic>\u2009=\u20090.10) and the recurrence of gout flares within 28\u201330\u00a0days (OR 0.78; 95% CI 0.29 to 2.09; I<jats:sup>2<\/jats:sup>, 0%; <jats:italic>p<\/jats:italic>\u2009=\u20090.62).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Initiation of ULT during an acute gout flare did not prolong the duration of the flare. However, larger sample size studies are needed to confirm this finding.<\/jats:p>\n                <jats:p><jats:italic>Trial registration number<\/jats:italic> PROSPERO (CRD42021234581).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-022-00236-5","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T12:03:03Z","timestamp":1643457783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The effect of initiation of urate-lowering treatment during a gout flare on the current episode: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-1689","authenticated-orcid":false,"given":"Ertao","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongling","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dabin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"issue":"10","key":"236_CR1","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"236_CR2","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447\u201361.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"236_CR3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72(6):879\u201395.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"236_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.rdc.2005.10.003","volume":"32","author":"HR Schumacher","year":"2006","unstructured":"Schumacher HR, Chen LX. Newer therapeutic approaches: gout. Rheumatic Dis Clin N Am. 2006;32(1):235\u201344.","journal-title":"Rheumatic Dis Clin N Am"},{"issue":"23","key":"236_CR5","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361.","journal-title":"N Engl J Med"},{"issue":"12","key":"236_CR6","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/rheumatology\/kem178","volume":"46","author":"WJ Taylor","year":"2007","unstructured":"Taylor WJ, Schumacher HR, Singh JA, Grainger R, Dalbeth N. Assessment of outcome in clinical trials of gout\u2014a review of current measures. Rheumatology. 2007;46(12):1751\u20136.","journal-title":"Rheumatology"},{"issue":"8","key":"236_CR7","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3899\/jrheum.081296","volume":"36","author":"C Barber","year":"2009","unstructured":"Barber C, Thompson K, Hanly JG. Impact of a rheumatology consultation service on the diagnostic accuracy and management of gout in hospitalized patients. J Rheumatol. 2009;36(8):1699\u2013704.","journal-title":"J Rheumatol"},{"issue":"5","key":"236_CR8","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/art.22767","volume":"57","author":"S Ja","year":"2007","unstructured":"Ja S, Js H, Jp T, Sm A. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57(5):822\u20139.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"236_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"236_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.amjmed.2012.05.025","volume":"125","author":"TH Taylor","year":"2012","unstructured":"Taylor TH, Mecchella JN, Larson RJ, Kerin KD, MacKenzie TA. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med. 2012;125(11):1126\u201334.","journal-title":"Am J Med"},{"issue":"3","key":"236_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/RHU.0000000000000235","volume":"21","author":"EM Hill","year":"2015","unstructured":"Hill EM, Sky K, Sit M, Collamer A, Higgs J. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. JCR-J Clin Rheumatol. 2015;21(3):120\u20135.","journal-title":"JCR-J Clin Rheumatol"},{"issue":"6","key":"236_CR12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDONALD PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273\u201382.","journal-title":"J Rheumatol"},{"issue":"5","key":"236_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jbspin.2020.03.017","volume":"87","author":"R Sun","year":"2020","unstructured":"Sun R, Lu J, Li H, Cheng X, Xin Y, Li C. Evaluation of febuxostat initiation during an acute gout attack: a prospective, randomized clinical trial. Jt Bone Spine. 2020;87(5):461\u20136.","journal-title":"Jt Bone Spine"},{"key":"236_CR14","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1093\/rheumatology\/keaa908","volume":"60","author":"E Jia","year":"2021","unstructured":"Jia E, Zhang Y, Ma W, Li B, Geng H, Zhong L, et al. Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial. Rheumatology (Oxford). 2021;60:4199\u2013204.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"236_CR15","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00296-016-3579-z","volume":"36","author":"F Eminaga","year":"2016","unstructured":"Eminaga F, Le-Carratt J, Jones A, Abhishek A. Does the initiation of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. Rheumatol Int. 2016;36(12):1747\u201352.","journal-title":"Rheumatol Int"},{"issue":"302","key":"236_CR16","first-page":"409","volume":"37","author":"RC Fraser","year":"1987","unstructured":"Fraser RC, Davis RH, Walker FS. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. J R Coll Gen Pract. 1987;37(302):409\u201311.","journal-title":"J R Coll Gen Pract"},{"issue":"2","key":"236_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s10067-020-05215-z","volume":"40","author":"X Zhang","year":"2021","unstructured":"Zhang X, Tang Y, Wang M, Wang D, Li Q. The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials. Clin Rheumatol. 2021;40(2):701\u201310.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"236_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","volume":"77","author":"H Yamanaka","year":"2018","unstructured":"Yamanaka H, Tamaki S, Ide Y, Kim H, Inoue K, Sugimoto M, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77(2):270\u20136.","journal-title":"Ann Rheum Dis"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-022-00236-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-022-00236-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-022-00236-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T12:19:09Z","timestamp":1643458749000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-022-00236-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["236"],"URL":"https:\/\/doi.org\/10.1186\/s42358-022-00236-5","relation":{},"ISSN":["2523-3106"],"issn-type":[{"type":"electronic","value":"2523-3106"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors report no conflict of interest pertinent to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}